Announcements Trials
Browse Landscape

Phase

Phase 2 50Phase 1 41Phase 1/2 23Phase 3 5Phase NA 2Phase EARLY_PHASE1 2Phase 4 1Phase 2/3 1

Status

Recruiting 3Completed 3Unknown 2Withdrawn 1Terminated 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

Saline Solution 6Fentanyl 6Sodium Chloride 5Letrozole 5Dexamethasone 5Pregabalin 4Ketamine 4Goserelin 4Gemcitabine 4Bevacizumab 4Tranexamic Acid 3Photochemotherapy 3Pemetrexed 3Paclitaxel 3Metformin 3Leuprolide 3Docetaxel 3Cyclophosphamide 3Carboplatin 3Capecitabine 3Acetaminophen 3ulipristal acetate 2sodium glycididazole 2nilotinib 2liposomal doxorubicin 2human papillomavirus vaccine, L1 type 16, 18 2flurbiprofen axetil 2fludarabine 2fluciclovine F-18 2epoetin beta 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Terminated × Lenalidomide × Clear all
NCT03173092 2026-05-04

A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)

Takeda

Phase 4 Terminated
141 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡